首页> 外文期刊>Respiration: International Review of Thoracic Diseases >Safety of endobronchial ultrasound-guided transbronchial needle aspiration for patients taking clopidogrel: A report of 12 consecutive cases
【24h】

Safety of endobronchial ultrasound-guided transbronchial needle aspiration for patients taking clopidogrel: A report of 12 consecutive cases

机译:氯吡格雷行支气管内超声引导经支气管针吸术的安全性:连续12例报告

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Clopidogrel is an oral agent commonly used for primary or secondary prevention of cardiovascular disease. It is associated with an increased risk of bleeding during some medical and surgical procedures. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a new bronchoscopic technique used to accurately biopsy intrathoracic structures during flexible bronchoscopy. It is currently unknown whether clopidogrel increases bleeding complications during EBUS-TBNA procedures. Objectives: To evaluate the safety of clopidogrel use in EBUS-TBNA by identifying consecutive cases of EBUS-TBNA procedures performed on patients taking clopidogrel. Methods: A retrospective review of a prospectively collected quality improvement database from 1,100 consecutive pulmonary procedures performed by an interventional pulmonologist (D.R.S.) at the University of Calgary from July 1st, 2007 to April 1st, 2011 was performed. Results: Twelve cases of EBUS-TBNA procedures performed on patients taking clopidogrel were identified. Mean age was 74 years (range 61-85). Seven patients (66.7%) were taking aspirin in addition to clopidogrel. There was no significant bleeding seen in any cases at the time of bronchoscopy and no additional complications were identified during follow-up (at least 4 weeks; median follow-up 3 months). Conclusions: This series of 12 cases suggests that EBUS-TBNA can be performed safely by experienced operators in patients taking clopidogrel. Nevertheless, until larger prospective studies confirm this hypothesis, proceeding to EBUS-TBNA without first withdrawing clopidogrel should only be performed in situations where the risk of short-term thrombosis is believed to outweigh the (theoretical) risk of bleeding.
机译:背景:氯吡格雷是一种通常用于一级或二级预防心血管疾病的口服药物。在某些医学和外科手术过程中,它会增加出血风险。支气管内超声引导的经支气管穿刺针抽吸术(EBUS-TBNA)是一种新的支气管镜检查技术,用于在柔性支气管镜检查期间准确地活检胸腔内结构。目前尚不清楚氯吡格雷是否会在EBUS-TBNA手术期间增加出血并发症。目的:通过确定连续服用氯吡格雷的患者进行EBUS-TBNA手术的病例,以评估氯吡格雷在EBUS-TBNA中使用的安全性。方法:对2007年7月1日至2011年4月1日由卡尔加里大学的介入性肺病学家(D.R.S.)进行的1100例连续肺手术收集的前瞻性收集的质量改善数据库进行了回顾性研究。结果:确定了十二例对服用氯吡格雷的患者进行的EBUS-TBNA手术。平均年龄为74岁(范围61-85)。除氯吡格雷外,七名患者(66.7%)正在服用阿司匹林。在任何情况下,支气管镜检查均未见明显出血,且在随访期间(至少4周;中位随访3个月)未发现其他并发症。结论:这一系列的12例病例表明,有经验的操作人员对服用氯吡格雷的患者可以安全地进行EBUS-TBNA。然而,直到更大规模的前瞻性研究证实了这一假设,才应在认为短期血栓形成的风险大于出血的(理论上)风险的情况下进行不首先撤出氯吡格雷的EBUS-TBNA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号